Utilized for long-term maintenance treatment of bronchospasm in patients with COPD.
Trade name Tudorza Pressair
A long-acting, inhaled muscarinic antagonist approved as a maintenance treatment for chronic obstructive pulmonary disease (COPD).
Has potent antagonism of muscarinic receptors, with a long residence time at M3 receptors and a shorter residence time at M2 receptors, with potential to provide sustained bronchodilation.
Rapidly hydrolysed in plasma, unlike other currently available antimuscarinics including tiotropium, resulting in very low and transient systemic exposure, with a reduced potential for systemic side effects.
Associated with a low systemic bioavailability and favorable safety profile of single and multiple doses.
Delivered via a novel, multidose dry powder inhaler.
Asked consistently improved morning. Those long function at 12 weeks or 20 feet four weeks versus placebo.
Has significant improvement in morning predose lung functions at 12 and 24 weeks versus placebo.
No differences in efficacy or safety between individuals older than 70 years and younger than 70 years.
Common side effects less than 7% and include headache, nasopharyngitis, and cough.
Incidence of common anti-cholinergic side effects less than 1%, including dry mouth, constipation, tachycardia, and
urinary retention.
Not indicated for the initial treatment of acute episodes of bronchospasm, i.e. rescue therapy.
Maybe associated with paradoxical broncospasm, and immediate hypersensitivity reactions.
Should be used with caution in patients with narrow angle glaucoma, and urinary retention.
Recommended dose one oral inhalation 400 µg, twice daily.